Nettoomsättningen i det andra kvartalet 2021 uppgick till 8,9 mkr (2,9 mkr), vilket motsvarar en tillväxt om ca.
Sivers nettoomsättning i Q2 uppgick till 27 mkr (21,5) och EBITDA till −20 mkr (−9).
Nettoomsättningen i kvartalet uppgick till 58,1 mkr vilket motsvarar en tillväxt om 226%.
Försäljningen under H1 (rapporterar halvårsvis) utvecklades bättre än vår prognos och ökade med 124 procent till 8,3 mkr (3,7), förväntat 7,...
Soltech rapporterar ett andra kvartal präglat av tillväxt och fortsätter där-med på den starka inled...
Första kliniska effektdata på COVID-19 vaccinet ABNCoV-2 gav lovande resultat.
Redeye initiates coverage of Cereno Scientific, a biotech company developing drugs to treat both rare and common cardiovascular diseases.
Redeye was encouraged to see strong gross margins and healthy growth in the second quarter.
Redeye has a positive take on Westpay’s operational development and financial KPIs.
LeoVegas rapporterar totala intäkter för det andra kvartalet på 96,8 miljoner euro (110,7), vilket m...
Key takes from the Q2’21 report Organoclick reported its Q2 results this morning, which were clearly...
COVID-19 lockdown measures continue to pressure in Q2’21 Moment reported Q2’21 total income of SEK 45m (SEK 20m in government aid), which wa...
Muted off-season quarter with limited impact on full year DistIT delivered relatively soft results w...
USD 9m EBITDA, in line with ABGSCe at USD 9.1m Report unlikely to trigger significant revisions Webc...
Redeye notes that Heliospectra’s Q2 numbers are on par with Q1 and mainly in line with our expectati...
We reiterate our mid-point DCF-based equity value of SEK 55 per share for Nelly Group.
Given we had lowered our estimates ahead of the results, Q2 was a slight disappointment.
Redeye is encouraged by the progress of KL1333 ahead of an expected major capital raise to fund the ...
Q2’21 an eventful quarter with Viscaria re-opening Copperstone reported sales of SEK 0m (ABGSCe 0m) ...
Functional Wood the big explainer OrganoClicks Q2 report came in below our expectations.
Redeye finds only minor deviations in the Q2 report vs our expectations.
Imponerar med både tillväxt och resultat Gullberg & Jansson rapporterar ett starkt andra kvartal prä...
Redeye maintains its view of Nanexa and base case of SEK 9.
Blandat kompott i Q2 Oasmia överraskade i Q2 med Apealea-intäkter och slog därmed våra förväntningar...
Redeye provides its initial take on Westpay’s Q2 report.
Redeye’s estimates were all and all in line with Q2 numbers.
Q3: Healthy organic growth but adj. EBIT lower than last year Atvexa reported Q3 sales of SEK 576m (...
